AI assistant
Altimmune, Inc. — Director's Dealing 2024
Feb 2, 2024
33207_dirs_2024-02-01_aec2a7e2-e043-4d12-9029-19bfd1dfcf76.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Altimmune, Inc. (ALT)
CIK: 0001326190
Period of Report: 2024-01-30
Reporting Person: Garg Vipin K (Director, President and CEO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-01-30 | Common Stock, par value $0.0001 | M | 26775 | — | Acquired | 276030 | Direct |
| 2024-01-30 | Common Stock, par value $0.0001 | F | 11697 | $9.80 | Disposed | 264333 | Direct |
| 2024-01-31 | Common Stock, par value $0.0001 | A | 7889 | $2.69 | Acquired | 272222 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-01-30 | Restricted Stock Units | $ | M | 26775 | Disposed | Common Stock, par value $0.0001 (26775) | Direct |
Footnotes
F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested.
F2: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs.
F3: These shares were purchased due to participation by the reporting individual in the Issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from August 1, 2023 through January 31, 2024.
F4: In accordance with the ESPP, these shares were purchased based on 85% of the opening price of the issuer's common stock on August 1, 2023.
F5: The RSUs become vested in substantially equal annual installments over the 4 years following January 30, 2023, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date.